We have heard WQ spinning off from Millennium, either in the form of a carve-out or larger capacity / lower return version, on-and-off these few years. This week we read that WQ will launch a 170/70 fund trading equities. The fund is expected to raise USD10bn, given that WQ is a rather big part of Millennium. This time it seems quite real because I keep seeing Igor’s name on the cap intro conference circuit. Should investors expect the new WQ fund to perform like Millennium?
New York Broadfin Capital is a global equity healthcare manager founded in 2005 achieving its returns through the consistent application of a value-oriented investment strategy based on deep, fundamental research. Drawing on its partners’ research and investment experience in the medical technology, pharmaceutical, and biotechnology sectors, the Broadfin Healthcare Fund’s exposure is predominantly in medical technology and pharmaceutical/ specialty pharma/ biotech stocks. The
New York The 1798 Volantis fund is an actively managed UK Small Cap Long Equity strategy that launched in May 2002. The investment objective of the fund is to provide investors with long term capital growth by taking high conviction positions, primarily in the securities of UK listed smaller companies. These companies predominantly have a market cap of below £1bn with the team particularly focusing on companies with a market cap below £300mn. The team comprises of eight inves
Hong Kong The BosValen Master Fund employs a long/ short equity strategy with an Asian focus, geographical focus on Pan-Asia within a global context. Investments are generally in companies located in Asia or whose businesses are subject to substantial influence from Asian economies. Typically, the portfolio will have 60-80 investments with 40-60% of gross exposure in Greater China, 10-25% in Japan and the rest of Asia and then 25-35% outside of Asia, including ADRs. Fund Deta